Table 3.

AORs associated with HCC by race/ethnicity (aOR associated with metformin use was adjusted for covariates, inverse propensity scores weighting of metformin use for each race/ethnic group, and inverse propensity scores weighting of race/ethnicity group membership)

	NHW	NHAA	Hispanics	P‐values for difference between race/ethnicity groups
	aOR (95% CI)	aOR (95% CI)	aOR (95% CI)	NHAA/NHW	Hispanics/NHW	Hispanics/NHAA
Metformin	0.570 (0.400, 0.810)	0.350 (0.250, 0.470)	0.310 (0.220, 0.430)	0.025	0.008	0.31
Statin use	0.442 (0.317, 0.616)	0.727 (0.298, 1.770)	0.192 (0.046, 0.794)	0.152	0.131	0.06
Beta blocker use	1.185 (0.857, 1.637)	0.466 (0.199, 1.089)	0.164 (0.037, 0.734)	0.022a	0.006a	0.118
Age (y)	1.019 (1.003, 1.034)	1.019 (0.984, 1.055)	0.884 (0.807, 0.969)	0.50	0.001	0.002
Charlson comorbidity	0.981 (0.967, 0.997)	0.981 (0.948, 1.016)	1.131 (1.032, 1.239)	0.50	0.001a	0.002
ΔA1C (%)	1.140 (0.989, 1.316)	1.277 (0.964, 1.692)	0.750 (0.446, 1.261)	0.24	0.064	0.039
ΔBMI (kg/m2)	0.977 (0.962, 0.991)	0.996 (0.984, 1.008)	1.220 (0.796, 1.869)	0.024a	0.154	0.176
ΔLDL (mg/L)	1.013 (1.007, 1.019)	0.997 (0.987, 1.007)	1.026 (0.995, 1.058)	0.003	0.219	0.041a
Neighborhood poverty (%)	1.005 (0.980, 1.031)	0.946 (0.886, 1.010)	0.938 (0.848, 1.037)	0.046	0.096b	0.445
Neighborhood High School completion (%)	1.062 (1.036, 1.088)	0.883 (0.780, 1.000)	0.933 (0.789, 1.103)	0.002	0.067	0.304
Neighborhood public Health insurance coverage (%)	0.992 (0.971, 1.013)	0.982 (0.933, 1.035)	1.016 (0.935, 1.105)	0.365	0.293	0.249
Neighborhood private Health insurance coverage (%)	1.016 (0.997, 1.036)	1.008 (0.951, 1.070)	1.025 (0.952, 1.101)	0.399	0.416	0.367

aOR, adjusted odds ratios; BMI, body mass index; HCC, hepatocellular carcinoma; LDL, low‐density lipoprotein; NHAA, non‐Hispanic African American; NHW, non‐Hispanic white.

^aModel with interactions involving race/ethnicity suggested nonsignificant interaction effect.

^bModel with interactions involving race/ethnicity suggested significant interaction effect.